Table 4.
Meta-regression analysis of heterogeneity for overall survival.
| Moderators | Variables of regression | HRinteraction (95% CI) | P-value of regression | I2 | Cochrane Q (P-value) |
|---|---|---|---|---|---|
| Year | Year | 1.001(0.990–1.012) | 0.840 | 81.69% | < 0.001 |
| Sample size | Sample size | 2.578(0.674–9.860) | 0.166 | 43.18% | 0.152 |
| Follow up | Follow up | 0.741(0.076–7.236) | 0.796 | 72.89% | < 0.001 |
| Country | Intercept | 1.648(1.291–2.104) | < 0.001 | 71.56% | < 0.001 |
| Germany | 1.001(0.334–2.997) | 0.999 | 71.56% | < 0.001 | |
| Hungary | 0.388(0.143–1.051) | 0.063 | 71.56% | < 0.001 | |
| Iran | 1.523(0.380–6.105) | 0.553 | 71.56% | < 0.001 | |
| Japan | 1.134(0.463–2.775) | 0.783 | 71.56% | < 0.001 | |
| Korea | 1.079(0.695–1.675) | 0.736 | 71.56% | < 0.001 | |
| Netherlands | 0.600(0.285–1.263) | 0.178 | 71.56% | < 0.001 | |
| Spain | 1.330(0.405–4.374) | 0.638 | 71.56% | < 0.001 | |
| USA | 0.605(0.302–1.215) | 0.158 | 71.56% | < 0.001 | |
| Tumor type | Intercept | 1.716(1.055–2.792) | 0.030 | 75.22% | < 0.001 |
| Colorectal cancer | 0.543(0.293–1.008) | 0.053 | 75.22% | < 0.001 | |
| Diffuse large B cell lymphoma | 2.786(0.559–13.892) | 0.211 | 75.22% | < 0.001 | |
| Endometrial carcinoma | 0.629(0.082–4.849) | 0.657 | 75.22% | < 0.001 | |
| Esophageal squamous cell carcinoma | 1.044(0.412–2.640) | 0.928 | 75.22% | < 0.001 | |
| Gastric Cancer | 0.851(0.442–1.638) | 0.630 | 75.22% | < 0.001 | |
| Hepatocellular Carcinoma | 1.168(0.574–2.373) | 0.668 | 75.22% | < 0.001 | |
| Laryngeal and hypopharyngeal carcinomas | 0.326(0.078–1.370) | 0.126 | 75.22% | < 0.001 | |
| NSCLC | 1.071(0.521–2.204) | 0.852 | 75.22% | < 0.001 | |
| Osteosarcoma | 0.960(0.384–2.399) | 0.930 | 75.22% | < 0.001 | |
| Ovarian cancer | 1.135(0.478–2.692) | 0.774 | 75.22% | < 0.001 | |
| Pancreatic ductal adenocarcinoma | 0.961(0.294–3.144) | 0.948 | 75.22% | < 0.001 | |
| Pelvis chondrosarcoma | 0.711(0.080–6.345) | 0.760 | 75.22% | < 0.001 | |
| Renal cell carcinoma | 2.208(0.520–9.383) | 0.283 | 75.22% | < 0.001 | |
| Soft tissue sarcoma | 5.863(1.115–30.823) | 0.037 | 75.22% | < 0.001 | |
| Uterine cervical cancer | 0.880(0.208–3.727) | 0.862 | 75.22% | < 0.001 | |
| Race | Intercept | 1.705(1.414–2.056) | < 0.001 | 73.32% | < 0.001 |
| Caucasian | 0.619(0.411–0.932) | 0.022 | 73.32% | < 0.001 | |
| Sample type | Intercept | 1.430(0.353–5.799) | 0.617 | 81.72% | < 0.001 |
| Tissue | 1.097(0.267–4.510) | 0.898 | 81.72% | < 0.001 |
HRinteraction, interaction effect calculated by meta-regression; Positive direction indicates that possible moderators might strengthen OS in the SIRT1 overexpression relative to underexpression. Bold italics indicate statistically significant values (P < 0.05).